VAN BEEK JEROEN B
SEC CIK 1743662 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KLRS | Kalaris Therapeutics, Inc. | Chief Commercial Off | 333.7K | — | $3.09M | 21 | 2021-02-17 | 2022-11-16 |
Most active insiders at KLRS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Samsara Opportunity Fund, L.P. | 10% | $5.00M | — |
| 2 | AKKARAJU SRINIVAS | Dir, 10% | $1.18M | — |
| 3 | Hagen Brett R | CAO | — | $12.9K |
VAN BEEK JEROEN B made no open-market trades at KLRS in the last 12 months.
Transactions 21
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-18 | 2022-11-16 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $7.50 | -16.1K | 333.7K | -5% | -$120.6K | |
| 2022-11-15 | 2022-11-11 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $8.20 | -36.6K | 349.8K | -9% | -$300.1K | |
| M | 2022-11-10 | 2022-11-08+ | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $8.00 | -13.4K | 399.5K | -3% | -$107.3K |
| A | 2022-10-26 | 2022-10-20 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $9.36 | -1,070 | 399.8K | -0.3% | -$10.0K |
| 2022-10-24 | 2022-10-19 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $9.36 | -1,070 | 399.8K | -0.3% | -$10.0K | |
| 2022-09-06 | 2022-09-02 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $7.89 | -493 | 400.9K | -0.1% | -$3,890 | |
| 2022-08-17 | 2022-08-16 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | A - Grant | $0.00 | +15.0K | 401.4K | +4% | $0 | |
| 2022-08-17 | 2022-08-16 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $8.30 | -15.6K | 386.4K | -4% | -$129.4K | |
| 2022-07-21 | 2022-07-20 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $5.21 | -1,058 | 402.0K | -0.3% | -$5,512 | |
| D | 2022-07-06 | 2022-07-01 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | A - Grant | $0.00 | +14.0K | 403.0K | +4% | $0 |
| D | 2022-07-06 | 2022-06-03 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $3.63 | -515 | 389.0K | -0.1% | -$1,869 |
| 2022-05-18 | 2022-05-17 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $4.40 | -15.3K | 389.5K | -4% | -$67.2K | |
| 2022-04-22 | 2022-04-20 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $6.68 | -852 | 404.8K | -0.2% | -$5,691 | |
| D | 2022-04-04 | 2022-01-18 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | A - Grant | $0.00 | +23.3K | 405.6K | +6% | $0 |
| 2022-03-03 | 2022-03-02 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $9.01 | -516 | 382.4K | -0.1% | -$4,649 | |
| 2022-02-18 | 2022-02-16 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $8.32 | -15.3K | 382.9K | -4% | -$127.5K | |
| 2022-01-24 | 2022-01-20 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $8.75 | -4,656 | 398.2K | -1% | -$40.7K | |
| 2021-12-03 | 2021-12-02 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $17.06 | -514 | 402.9K | -0.1% | -$8,769 | |
| 2021-11-18 | 2021-11-16 | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $21.13 | -15.2K | 403.4K | -4% | -$321.2K | |
| M | 2021-10-01 | 2021-09-29+ | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $25.14 | -16.6K | 422.0K | -4% | -$416.9K |
| M | 2021-09-20 | 2021-02-17+ | KLRS | Kalaris Therapeutics, Inc. | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $26.57 | -53.1K | 490.1K | -10% | -$1.41M |
Purchase Sale Sale after option exercise All abbreviations